[1]李雅楠,杨会涛,谷 贺,等.NSCLC患者外周血自然细胞毒性受体NKp46，NKp30，NKG2A和NKG2D表达水平及临床价值研究[J].现代检验医学杂志,2025,40(06):110-115.[doi:10.3969/j.issn.1671-7414.2025.06.020]
　LI Yanan,YANG Huitao,GU He,et al.Expression Levels of NKp46, NKp30, NKG2A and NKG2D on Natural Cytotoxicity Receptor in Peripheral Blood of NSCLC Patients and Its Clinical Diagnostic Value[J].Journal of Modern Laboratory Medicine,2025,40(06):110-115.[doi:10.3969/j.issn.1671-7414.2025.06.020]
点击复制

NSCLC患者外周血自然细胞毒性受体NKp46，NKp30，NKG2A和NKG2D表达水平及临床价值研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年06期
页码:
110-115
栏目:
论著
出版日期:
2025-11-15

文章信息/Info

Title:
Expression Levels of NKp46, NKp30, NKG2A and NKG2D on Natural Cytotoxicity Receptor in Peripheral Blood of NSCLC Patients and Its Clinical Diagnostic Value
文章编号:
1671-7414（2025）06-110-06
作者:
李雅楠a，杨会涛a，谷 贺b，李 进b
河北中医药大学附属石家庄平安医院 a.检验科；b.肿瘤科，石家庄 050021
Author(s):
LI Ya’nana，YANG Huitaoa，GU Heb，LI Jinb
a. Department of Clinical Laboratory；b. Department of Oncology， Affiliated Shijiazhuang Ping’an Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050021, China
关键词:
非小细胞肺癌; 自然杀伤细胞; 自然细胞毒性受体; 流式细胞术
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.06.020
文献标志码:
A
摘要:
目的探究非小细胞肺癌（NSCLC）患者外周血自然细胞毒性受体（NCR）NKp46，NKp30，NKG2A和NKG2D的表达水平及其临床价值。方法选取河北中医药大学附属石家庄平安医院2021年10月～2022年8月收治的NSCLC患者50例作为研究组（NSCLC组），另选取同期健康体检者20例作为对照组。收集外周静脉血标本，采用流式细胞仪检测NKp46，NKp30，NKG2A和NKG2D在NK细胞表面的表达阳性率。收集患者临床资料，采用单因素方差分析/t检验分析NKp46，NKp30，NKG2A和NKG2D的表达阳性率与病理类型、TNM分期、生存时间的相关性。结果与对照组相比，NSCLC组外周血自然细胞毒性受体NKp46表达阳性率显著升高（42.09%±18.55%vs25.92%±14.03%），差异具有统计学意义（t=3.511，P＜0.01）；NKG2A，NKG2D和NKp30在两组之间的表达阳性率比较，差异无统计学意义（t=0.447，0.536，1.941，均P＞0.05）。对NK细胞进行亚群分析，与对照组相比，NSCLC组CD56brightCD16+NK亚群比例显著升高（3.76%±1.91%vs2.42%±0.85%），差异具有统计学意义（t=3.017，P＜0.01）；NKp46在CD56brightCD16+NK亚群和CD56dimCD16+NK亚群的表达阳性率均显著升高（59.64%±21.12%vs43.91%±16.04%，51.32%±19.84%vs38.69%±15.12%），差异具有统计学意义（t=2.999，2.562，均P＜0.01）。NKp46，NKp30，NKG2A和NKG2D在肺鳞癌和肺腺癌的表达阳性率比较，差异无统计学意义（t=0.188～0.600，均P＞0.05）；NKp46在NSCLC组外周血NK细胞的表达阳性率随TNM分期进展而逐渐降低，但差异无统计学意义（F=2.381，P=0.10）；与生存期≤12个月患者相比，NKp46在生存期＞12个月患者的表达阳性率显著升高（49.77%±17.52%vs36.71%±15.41%），差异具有统计学意义（t=2.716，P＜0.01）。结论NKp46在NSCLC患者外周血NK细胞的表达阳性率升高，主要集中在CD56dimCD16+NK亚群和CD56brightCD16+NK亚群。NKp46的表达与NSCLC生存期有关，与病理类型无关。外周血自然细胞毒性受体NKp46可作为NSCLC诊断和预后评估的潜在标志物。
Abstract:
Objective To analyze the expression levels of natural cytotoxicity receptor (NCR) NKp46, NKp30, NKG2A and NKG2D in peripheral blood of non-small cell lung cancer (NSCLC) patients and its clinical diagnostic value. Methods A total of 50 NSCLC patients admitted to Affiliated Shijiazhuang Ping’an Hospital of Hebei University of Chinese Medicine from October 2021 to August 2022 were selected as the study group (NSCLC group). Meanwhile, 20 healthy individuals who underwent physical examinations during the same period were selected as the control group. Peripheral blood samples were collected and the positive expression rate of NKp4, NKp30, NKG2A and NKG2D on NK cell surface was detected by flow cytometry. Clinical data from patients was collected and the correlation between the positive expression rate of NKp46, NKp30, NKG2A and NKG2D and pathological type, TNM staging and survival time were analyzed by One-way ANOVA/t test. Results Compared to control group, the positive expression rate of NKp46 on NK cells in peripheral blood of NSCLC patients were significantly elevated (42.09%±18.55% vs 25.92%±14.03%), the difference was statistically significant (t=3.511, P＜0.01). Comparison of the positive expression rates of NKG2A, NKG2D and NKp30 between the two groups and the differences were not statisticany significant (t=0.447，0.536，1.941，all P ＞ 0.05). Subgroup analysis of NK cells revealed a significant increase in the proportion of CD56brightCD16+ NK subgroups in NSCLC group compared to control group (3.76%±1.91% vs 2.42%±0.85%), the difference was statistically significant (t=3.017, P ＜ 0.01). The positive expression rate of NKp46 in the CD56brightCD16+NK subgroup and CD56dimCD16+ NK subgroup significantly increased（59.64%±21.12% vs 43.91%±16.04%，51.32%± 19.84% vs 38.69%±15.12%）, the differences were statistically significant (t=2.999, 2.562, all P ＜ 0.01). There was no significant difference in the positive expression rate of NKp46, NKG2A, NKG2D and NKp30 among squamous cell carcinoma and adenocarcinoma in lung (t=0.188 ～ 0.600, all P ＞ 0.05). As TNM progresses, the positive expression rate of NKp46 on peripheral blood NK cells in NSCLC patients decreases, but the trend is of no statistical difference (F=2.381, P=0.10). Compared to patients with survival period ≤ 12 months, the positive expression rate of NKp46 in patients with survival period > 12 months was significantly higher (49.77%±17.52% vs 36.71%±15.41%), the difference was statistically significant (t=2.716, P＜0.01). Conclusion The positive expression rate of NKp46 in peripheral blood NK cells of NSCLC patients is increased, mainly in the CD56dimCD16+ NK subgroup and CD56brightCD16+ NK subgroup. The expression of NKp46 is related to the survival time of NSCLC patients, but not to the pathological type. Peripheral blood NCR NKp46 can serve as a potential biomarker for the diagnosis and prognostic evaluation of NSCLC.

参考文献/References:

[1] XIA C F, DONG X S, LI H , et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical Journal, 2022, 135(5): 584-590.
[2] WANG M N, HERBST R S, BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nature Medicine, 2021, 27(8): 1345-1356.
[3] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Cancer statistics for the year 2020: an overview[J]. International Journal of Cancer, 2021, 149(4): 778-789.
[4] ETTINGER D S, WOOD D E, AISNER D L, et al. NCCN guidelines? insights: non-small cell lung cancer, version 2.2023[J]. Journal of the National Comprehensive Cancer Network , 2023, 21(4): 340-350.
[5] MANDELBOIM O, PORGADOR A. NKp46[J]. the International Journal of Biochemistry & Cell Biology, 2001, 33(12): 1147-1150.
[6] PAGE A, CHUVIN N, VALLADEAU-GUILEMOND J, et al. Development of NK cell-based cancer immunotherapies through receptor engineering[J]. Cellular& Molecular Immunology, 2024, 21(4): 315-331.
[7] BJ?RKSTR?M N K, LJUNGGREN H G, MICHA?LSSON J. Emerging insights into natural killer cells in human peripheral tissues[J]. Nature Reviews Immunology, 2016, 16(5): 310-320.
[8] WOAN K V, MILLER J S. Harnessing natural killer cell antitumor immunity: from the bench to bedside [J]. Cancer Immunology Research,2019, 7(11): 1742-1747.
[9] 中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南（2021版）[J].中华医学杂志,2021,101(23):1725-1757. Oncology Society of Chinese Medical Association， Chinese Medical Association Publishing House. Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer(2021 edition)[J]. National Medical Journal of China, 2021, 101(23): 1725-1757.
[10] BUCKLE I, JOHNSON A, ROJAS I L, et al. High dimensional analysis reveals distinct NK cell subsets but conserved response to stimulation in umbilical cord blood and adult peripheral blood[J]. European Journal of Immunology, 2023, 53(6): e2250118.
[11] WOLF N K, KISSIOV D U, RAULET D H. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy[J]. Nature Reviews Immunology, 2023, 23(2): 90-105.
[12] LIU S Z, GALAT V, GALAT Y, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development[J]. Journal of Hematology & Oncology, 2021, 14(1): 7.
[13] SIVORI S, PENDE D, BOTTINO C, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells[J]. European Journal of Immunology, 1999, 29(5): 1656-1666.
[14] MORVAN M G, LANIER L L. NK cells and cancer:you can teach innate cells new tricks[J]. Nature Reviews Cancer, 2016, 16(1): 7-19.
[15] HODGINS J J, KHAN S T, PARK M M, et al. Killers 2.0:NK cell therapies at the forefront of cancer control[J]. the Journal of Clinical Investigation, 2019, 129(9): 3499-3510.
[16] SHEHATA H M, DOGRA P, GIERKE S, et al. Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines in vitro [J]. Frontiers in Immunology, 2024, 15: 1341804.
[17] PRAGER I, LIESCHE C, VAN OOIJEN H, et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing[J]. the Journal of Experimental Medicine, 2019, 216(9): 2113-2127.
[18] GLASNER A, LEVI A, ENK J, et al. NKp46 receptor-mediated interferon-γ production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis[J]. Immunity, 2018, 48(1): 107-119,e4.
[19] SEN SANTARA S, LEE D J, CRESPO ?, et al. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells[J]. Nature, 2023, 616(7956): 348-356.
[20] GAUTHIER L, MOREL A, ANCERIZ N, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity[J]. Cell, 2019, 177(7): 1701-1713.e16.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(06):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(06):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华,齐宗利,张海祥,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Hua,QI Zong-li,ZHANG Hai-xiang,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(06):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目：石家庄市科学技术研究与发展计划项目（211200763）。
作者简介：李雅楠（1989-），女，医学硕士，硕士生导师，副主任检验技师，研究方向：临床检验诊断学，E-mail：niwawa941@163.com
。
更新日期/Last Update: 2025-11-15